2-{4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)sulfanyl]phenoxy}acetic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-{4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)sulfanyl]phenoxy}acetic acid
• 英文别名: 2-[4-[[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]phenoxy]acetic Acid
• 化学式: C₂₀H₁₆F₃NO₃S₂
• 分子量: 439.479
• InChiKey: DJWXMPYNYSBGOK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  29
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  113
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  5-(氯甲基)-4-甲基-2-[4-(三氟甲基)苯基]-1,3-噻唑 在 potassium carbonate 、 caesium carbonate 作用下， 以 甲醇 、 乙腈 为溶剂， 生成 2-{4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)sulfanyl]phenoxy}acetic acid
  参考文献：
  名称：

  Synthesis of the PPARβ/δ-selective agonist GW501516 and C4-thiazole-substituted analogs

  摘要：

  Sequential, position-selective, Pd-catalyzed cross-coupling reactions of 2,4-dibromo-5-hydroxymethylthiazole provided the scaffold for the synthesis of GW501516, the most potent PPAR beta/delta agonist yet described, and equally selective analogs at the thiazole-C4 position. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.09.060

文献信息

• Arylchalcogenoarylalkyl-substituted imidazolidine-2,4-diones, process for preparation thereof, medicaments comprising these compounds and use thereof
  申请人：JAEHNE Gerhard

  公开号：US20110046185A1

  公开（公告）日：2011-02-24

  The invention relates to compounds of formula (I) wherein the groups R and R′ A, D, E, G, L, p and R1 to R10 have the stated meanings and to their physiologically compatible salts. Said compounds are suitable, for example, as anti-obesity drugs.

  该发明涉及式(I)的化合物，其中基团R和R′ A、D、E、G、L、p以及R1到R10具有所述含义，以及它们的生理相容盐。所述化合物适用于例如作为抗肥胖药物。
• [EN] N-ALKYL PYRROLES AS HMG-COA REDUCTASE INHIBITORS<br/>[FR] PYRROLES DE N-ALKYL COMME INHIBITEURS DE L'HMG-COA-REDUCTASE
  申请人：WARNER LAMBERT CO

  公开号：WO2005056004A1

  公开（公告）日：2005-06-23

  HMGCo-A reductase inhibitor compounds useful as hypocholesterolemic and hypolipidemic compounds are provided. Also provided are pharmaceutical compositions of the compounds. Methods of making and methods of using the compounds are also provided. Formula (I).

  提供了作为降胆固醇和降脂化合物有用的HMGCo-A还原酶抑制剂化合物。还提供了这些化合物的药物组合物。还提供了制备这些化合物的方法和使用这些化合物的方法。公式（I）。
• [EN] SUBSTITUTED HETEROCYCLIC ACETAMIDES AS KAPPA OPIOID RECEPTOR (KOR) AGONISTS<br/>[FR] ACÉTAMIDES HÉTÉROCYCLIQUES SUBSTITUÉS EN TANT QU'AGONISTES DU RÉCEPTEUR OPIOÏDE KAPPA (KOR)
  申请人：REDDYS LAB LTD DR

  公开号：WO2013131408A1

  公开（公告）日：2013-09-12

  The present invention relates to a series of substituted compounds having the general formula (I), including their ste reoisomers and/or their pharmaceutically acceptable salts, wherein R1, R2, R3. R4, R5, and R6 are as defined herein. This invention also relates to methods of making these compounds including intermediates. The compounds of this invention are effective at the kappa (κ) opioid receptor (KOR) site. Therefore, the compounds of this invention are useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of central nervous system disorders (CNS), including but not limited to acute and chronic pain, and associated disorders, particularly functioning peripherally at the CNS.

  本发明涉及一系列具有通式（I）的取代化合物，包括它们的立体异构体和/或其药用盐，其中R1、R2、R3、R4、R5和R6如本文所定义。本发明还涉及制备这些化合物的方法，包括中间体。本发明的化合物在kappa（κ）阿片受体（KOR）位点上具有有效性。因此，本发明的化合物可用作药物剂，特别是在治疗和/或预防各种中枢神经系统疾病（CNS）方面，包括但不限于急性和慢性疼痛，以及相关疾病，尤其是在中枢神经系统的外周起作用。
• Novel imidazoles
  申请人：Bolton Louis Gary

  公开号：US20050239857A1

  公开（公告）日：2005-10-27

  Novel imidazoles are provided. The compounds are useful as HMGCo-A Reductase Inhibitor. Also provided are pharmaceutical compositions of the compounds. Methods of making and methods of using the compounds are also provided.

  提供了新型咪唑类化合物。这些化合物可用作HMGCo-A还原酶抑制剂。还提供了这些化合物的药物组合物。还提供了制备这些化合物的方法和使用这些化合物的方法。
• Novel pyrazole-based HMG CoA reductase inhibitors
  申请人：Choi Chulho

  公开号：US20060111422A1

  公开（公告）日：2006-05-25

  Novel compounds and pharmaceutical compositions useful as hypocholesterolemic and hypolipidemic agents are described. More specifically, potent inhibitors of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (“HMG CoA reductase”) are described. Methods of using such compounds and compositions to treat subjects, including humans, suffering from hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, Alzheimer's Disease, benign prostatic hypertrophy (BPH), diabetes and osteoporosis are also described.

  描述了作为降胆固醇和降脂血症药物的新化合物和制剂。更具体地，描述了对酶3-羟基-3-甲基戊二酰辅酶A还原酶（“HMG CoA还原酶”）的强效抑制剂。还描述了使用这些化合物和制剂来治疗患有高脂血症、高胆固醇血症、高甘油三酯血症、动脉粥样硬化、阿尔茨海默病、良性前列腺肥大（BPH）、糖尿病和骨质疏松症等疾病的受试者，包括人类的方法。